Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer ... Special features include reports on the latest ...

Researchers discover that inflammation and aging contribute to non-viral liver cancer development. Green tea's role in reversing some of the pathway dysregulation that may contribute to the cancer ...

California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is ...

like CRC and hepatocellular carcinoma (HCC), among others. “As we continue to explore the novel mechanism of action of CY-101 and its translation into meaningful clinical activity ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and ...

Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...